In this presentation from AAO 2016, Aleksandra Rachitskaya, MD, presents the following study results:

For Year 1: 

• All 3 anti-VEGF agents — Afilbercept, Bevacizumab, and Ranibizumab — are effective treatments for AMD-causing vision impairment.
• When initial visual acuity loss is mild, there is little difference in visual acuity at 1 year.
• When loss is worse, levels of initial visual acuity aflibercept is more effective at improving vision.

For Year 2:

• Vision gains (from baseline) were seen with all 3 drugs, with reduced number of injections and lasers in year 2.
• When initial visual acuity loss is mild, on average, there is still little difference in the three drugs.
• When loss is worse, levels of initial visual acuity Aflibercept was more effective at improving visual acuity versus Bevacizumbab, but not Ranibizumab.